In today's ACT Brief, we examine how game theory principles can improve CRO and vendor selection through ecosystem alignment, why clinical technology platforms must be purpose-built and fully integrated, and how pricing pressures and regulatory changes are reshaping pharmaceutical R&D investment.

: In today's ACT Brief, we examine how behavioral science applied during trial design and startup can identify recruitment barriers early, the importance of authentic community engagement over traditional outreach, and how large pharmaceutical companies are increasingly investing in rare disease development.

In today's ACT Brief, we examine Thermo Fisher's acquisition of Clario to expand clinical trial data infrastructure, how wearable devices and AI are reshaping patient monitoring workflows, and a collaboration between Merck and Quotient using somatic genomics to identify IBD drug targets.

In today's ACT Brief, we explore how AI can parse wearable data streams to identify subtle clinical patterns, FDA's four major policy shifts modernizing drug development and approval standards, and ongoing questions about regulatory consistency in rare disease pathways.

In today's ACT Brief, we explore how FDA clearance and reimbursement models support wearable adoption in clinical care, the importance of end-to-end data validation before patient enrollment, and FDA approval of a higher-dose semaglutide formulation for weight loss.

 In today's ACT Brief, we explore the data overload and alert fatigue challenges in integrating wearable data into clinical workflows, how cognitive and behavioral science can transform site readiness and training, and FDA's evolving guidance on rare disease trial design and evidence standards.

In today's ACT Brief, we explore how continuous remote monitoring enables early clinical interventions, FDA guidance on validating new approach methodologies as alternatives to animal testing, and the importance of transparent data collection in decentralized trials.

In today's ACT Brief, we explore how wearable data is informing real-world clinical decision-making, a statistical method that analyzes multiple patient outcomes simultaneously to improve trial design, and legal challenges to recent vaccine advisory committee changes.

In today's ACT Brief, we examine the technology infrastructure gap facing investigator-initiated trials, how transparency and community engagement drive vaccine adoption, and why workflow orchestration—not just digitization—delivers operational value in clinical research.

In today's ACT Brief, we explore the transparency demands of complex trial designs and synthetic controls, how measuring site readiness during training predicts protocol execution, and the FDA's streamlined biosimilar development pathway aimed at reducing drug costs.